These changes include mobilization of energy from peripheral muscle and fat sources and increased nutrient uptake by liver for protein synthesis. A large body of research has shown that many of the observed biological responses to infection are mediated by host-secreted cytokines.
S everal metabolic and physiologic alterations characteristically follow parasitic and bacterial infections. 1 These changes include mobilization of energy from peripheral muscle and fat sources and increased nutrient uptake by liver for protein synthesis. A large body of research has shown that many of the observed biological responses to infection are mediated by host-secreted cytokines. 2 One such cytokine, tumor necrosis factor (TNF), also termed cachectin, is believed to be responsible for the pathological state of cachexia associated with chronic infections. 34 Among the several host changes that frequently follow infection 5 -9 or TNF administration 10 is hypertriglyceridemia due to marked elevations of plasma very low density lipoproteins (VLDL). Decreased VLDL catabolism during infection is due, at least in part, to a loss of activity of lipoprotein lipase (LPL) in peripheral tissues. 5 LPL, which is bound to glycosaminoglycans on the vascular endothelial surface, 1112 is responsible for hydrolysis of triglycerides in plasma lipoproteins. The importance of endothelial cell-bound LPL in the hydrolysis of triglyceride-rich lipoproteins is supported by clinical observations. Patients with auto-antibodies to heparan sulfate molecules have marked hypertriglyceridemia and reduced levels of LPL activity in their postheparin plasma. 13 This is presumably due to antibody inhibition of the attachment of LPL to endothelial cells. Thus, events that reduce LPL interaction with endothelial cells can regulate its activity in vivo.
Several studies have shown that TNF dramatically alters a number of properties of endothelial cells. These changes include modulation of the hemostatic and coagulant properties of the cell surface, 1415 increased secretion of platelet-derived growth factor (PDGF), 16 and rapid release of arachidonic acid and eicosanoid products. 17 In addition to these effects on endothelial cells, TNF administration to animals 10 and humans 18 affects LPL activity in various tissues and produces hypertriglyceridemia. Injection of TNF into rats, mice, and guinea pigs 10 decreases adipose tissue LPL synthesis and activity. However, TNF increases LPL activity in heart, lung, liver, and plasma. 10 Thus, TNF redistributes LPL activity among various tissues. This may direct the flow of fatty acids away from storage sites during infection or inflammation. Because of the known actions of TNF on endothelial cells and the role of endothelial cell bound LPL in triglyceride clearance, we explored whether the binding of LPL to the endothelial cell surface is altered by TNF treatment.
1 day after the cells reached confluency. The cells were cultured at 37°C in a humidified atmosphere of 5% CO 2 in air in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, antibiotics [100 units/ml penicillin and 100 /ig/ml streptomycin (Hazelton Research Products, Lenexa, KS)], and glutamine (2 mM). The medium was replaced every other day. For some experiments, the cells were incubated for 18 hours with pertussis toxin (List Biological, Incambell, CA), 100 ng/ml, or for 3 hours with colchicine, 200
Purification of Bovine Milk Upoprotein Upase and Measurement of Enzyme Activity
LPL was purified from fresh bovine milk as described previously 20 with the method of Socorro et al. 21 Unpasteurized milk was adjusted to 0.4 M NaCI by the addition of solid NaCI and was centrifuged at 3000 g at 4°C to remove the cream. Heparin-agarose gel (Bio-Rad, Richmond, CA) (80 ml gel) was added to the skim milk (3.5) and incubated at 4°C for 18 hours on a platform rocker. The gel was washed consecutively with 20 mM of Tris-HCI buffer (pH 7.4) containing 0.4 M NaCI and then with 0.75 M NaCI, and was transferred to a column (2.5x20 cm). The enzyme was eluted with 20 mM of Tris-HCI buffer (pH 7.4) containing 1.5 M of NaCI. Protein was determined by the method of Lowry et al. 22 by using bovine serum albumin (BSA) as a standard. The purified enzyme was stored at -70°C. The purity of the enzyme preparation was established by sodium dodecyl sulfatepolyacrylamide gel electrophoresis with 4% to 30% gradient gels (Pharmacia Fine Chemicals, Piscataway, NJ). The purified enzyme had a specific activity of 30 mmol of oleic acid released/hr/mg of enzyme with the substrate described below. The triglyceride hydrolytic activity of the enzyme was measured with 100 y\ of the substrate emulsion described by Hietanen and Greenwood 23 containing 1.5 /imol of triolein (Nu-check Prep, Elysian, MN) and 1.6 /xCi of glycerol tri (9, H) oleate (Amersham, Arlington Heights, IL), 9 /xg of egg yolk phosphatidylcholine (Sigma Chemical, St. Louis, MO), sonicated in 67 jd of buffer (0.3 M of Tris-HCI, 3% BSA, pH 8.6), and 33 /J of heat-inactivated human serum as a source of apolipoprotein C-ll. The assay was carried out in a 37°C water bath for 60 minutes. The enzymatically released fatty acids were extracted as described by Belfrage and Vaughan, 24 and the radioactivity in 1 ml of the aqueous phase was counted by using 5 ml of scintillation fluid (Hydroflour, National Diagnostics, Manville, NJ) in a model 1800 liquid scintillation counter (Beckman Instruments, Palo Aito, CA).
Radlolodlnatlon of Upoprotein Upase
Purified LPL was radioiodinated as described previously 20 by using lactoperoxidase and glucose oxidase enzymes. The reaction mixture (1 ml) containing purified LPL (800 /xg), 20 mM of glucose, 1 mCi of Na 125 l (Amersham), 7.5 mg/ml of lactoperoxidase, and 1 mg/ml of glucose oxidase (Sigma) was incubated in 50 mM of Tris-HCI buffer (pH 7.4) for 5 minutes on ice. Radioiodinated LPL was then purified by heparin-Sepharose affinity chromatography. The labeled enzyme was stored at -70°C in the presence of 1% BSA. Radioactivity was measured by using a model 1274 gamma counter (LKB Instruments, Gaithersburg, MD). A typical preparation had a specific activity of about 500 cpm/ng LPL, and more than 90% of the counts were precipitated by 10% trichloroacetjc acid.
Binding of Upoprotein Upase to Endothelial Cells
The binding of LPL to endothelial cells was performed essentially as described previously. 20 On the day of the experiment, the culture medium was aspirated, and the cells were washed three times with 2 ml of fresh medium without fetal calf serum. All further steps were carried out using DMEM containing 3% BSA (Fraction V, Sigma). The cells were incubated at 37°C for 1 hour with 1 ml of DMEM containing BSA and 6 /*g 125 I-LPL and were then washed three times with DMEM, 3% BSA.
Release of Upoprotein Upase by TNF, PDGF, Quinacrine, Mellttln, Indomethacin, or Fatty Acld:BSA Solutions
The release of 12S I-LPL was studied by using cells to which LPL had been bound. The cells were incubated with 1 ml of media containing either recombinant human TNFa (Genentech, South San Francisco, CA), quinacrine, melittin, indomethacin (all from Sigma), purified PDGF, or fatty acid: BSA solutions at 37°C for 1 hour, unless otherwise stated. In some experiments, TNF was added together with either quinacrine or indomethacin. Fatty acid:BSA solutions were prepared by first dissolving the fatty acid (oleic or arachidonic acid) in isopropanol and then adding the solution to DMEM containing 0.44 mM BSA. 25 After the incubation, the media with the released 125 I-LPL were collected. The cells were then treated with 100 units of heparin (The Upjohn Co., Kalamazoo, Ml) for 15 minutes at 25°C to estimate the radioactive LPL protein remaining on the cells. Cell viability was routinely checked by trypan blue exclusion and was found to be unchanged under all conditions used.
Release of Radlolabeled Glycosamlnoglycans
Endothelial cells were grown as described above and were labeled by incubation for 3 days in DMEM containing 3S SO 4 (2.2 mCi/ml) and D-6-3 H-glucosamine (1 mCi/ml). At the end of the labeling period, the medium was removed, and the cells were rinsed three times with 2 ml of DMEM. The cells were then incubated with medium alone or with medium containing TNF or insulin (100 ng/ml) for 1 hour at 37°C. The media were collected, and the glycosaminoglycans and proteoglycans were precipitated with 95% ethanol containing 1.3% potassium acetate or cetylpyridinium chloride. The radioactivity was measured.
Mltogenlc Assay
Stimulation of 3 H-thymidine incorporation into the deoxyribonucleic acid of cultured BALB/C 3T3 cells 19 was measured by using media from TNF-treated or control endothelial cells. The 3T3 cells were pulse-labeled with 3 H-thymidine for 2 hours after stimulation for 15 to 17 hours. TNF was also added directly to 3T3 cells to determine whether it contained mitogenic activity.
Results
Cells with bound 125 I-LPL were incubated with increasing concentrations of TNF, and the release of 125 I-LPL into the media is shown in Figure 1 A. TNF addition resulted in a concentration-dependent release of 126 I-LPL, with a corresponding decrease in the amount of LPL remaining bound to the cells. The amount released reached a plateau at 100 ng of TNF per ml. Using 100 ng of TNF, the medium contained a threefold greater amount of 125 I-LPL released than did control medium. Similarly, TNF released LPL catalytic activity bound to endothelial cells and decreased the amount of cell-associated activity (results not shown).
The time course of the release of 125 I-LPL from the endothelial cells by TNF is shown in Figure 1B . The maximum release occurred at 45 minutes with no further increase. We have previously demonstrated that incubation with oleic add can release LPL bound to the endothelial cells. 20 The mechanism of release by oleic acid was postulated to be independent of any cellular metabolic event and due to direct interaction between oleic acid and LPL molecules. A comparison of the kinetics of 12S I-LPL release induced by TNF and oleic acid (Figure 1B) shows that oleic acid-induced release was more rapid and peaked by 20 minutes. These results suggested that TNF-induced release of LPL may require additional events other than a direct interaction between TNF and LPL molecules.
A requirement for endothelial cell metabolic event(s) in the TNF-induced release of cell-associated 12S I-LPL was suggested by the results of experiments in which release of LPL by TNF was studied at 4°C. Endothelial cells incubated at 4°C for 60 minutes with various concentrations of TNF (10 to 200 ng/ml) did not increase the release of 12S I-LPL, compared to a control incubation (only the 100 ng/ml TNF data point is shown) (Figure 2) . TNF affects the secretion of a number of proteins 216 and lipid molecules 217 by endothelial cells which may, in turn, affect the endothelial cell membrane. To examine whether a cell secretory event was required for LPL release, cells were pretreated with colchicine, a cytoskeletal disrupting agent, that blocks cell secretion. The effect of pretreatment with pertussis toxin on LPL release was also studied. This agent inactivates guanine nucleotide regulatory proteins and has previously been shown to block the TNF-mediated increase in eicosanoid production by endothelial cells. 17 Both colchicine and pertussis toxin abrogated the TNF-induced release of 16 PDGF is a cationic protein containing several basic amino acids capable of interaction with negatively charged endothelial cell surface glycosaminoglycans. 26 In the above experiments, endothelial cells incubated with TNF did acutely release PDGF-like mitogenic activity (Figure 3) . The maximum release was estimated to be less than 5 ng/ml. To determine if TNF-mediated release of cell surface-bound LPL was due to a competition between LPL and PDGF (secreted in response to TNF by endothelial cells) for the same binding sites on the cell surface, cells with 125 I-LPL bound were incubated with increasing concentrations of purified PDGF. As shown in Figure 4 , the addition of PDGF (up to 100 ng) failed to release 12S I-LPL bound to the endothelial cells. Thus, PDGF was unable to displace LPL from glycosaminoglycans on the endothelial cell surface.
Increasing amounts of arachidonic acid generated during TNF incubation with the cells may have affected the binding of LPL to the cell surface. TNF-induced release of arachidonic acid from bovine endothelial cells peaked at 15 minutes, 17 while release of LPL by TNF was maximal at 45 minutes (Figure 1 ). This time course and our previous studies which demonstrated LPL release from endothelial cells by some types of fatty acids 2027 support this hypothetical role for arachidonic acid. Therefore, the effects of incubation of endothelial cells with increasing molar ratios of arachidonic acid:BSA on membrane-associated LPL were investigated. Figure 4 shows that addition of increasing arachidonic acid:BSA molar ratios decreased the amount of LPL bound to the cells; there was a corresponding increase in the amount of LPL in the media.
The generation of arachidonic acid by endothelial cells in response to TNF is mediated by the activation of phospholipase A^1 7 In other cell types, phospholipase activation has been implicated in the actions of TNF. 28 Because addition of arachidonic acid:BSA solutions were able to release LPL from the cells, we directly examined the role of phospholipase Aj in release of LPL The addition of melittin (3 /ig/ml), a protein which has been shown to stimulate phospholipase A2 activity, 2930 resulted in the release of LPL from the cells (65% increase over control incubation, Figure 5 ). In another set of experiments, the effect of quinacrine (3 /xM), a phospholipase Ai inhibitor, 31 on TNF-induced release of LPL was examined. Incubation of cells bound with 125 I-LPL with quinacrine alone showed a slight decrease (15%) in the dissociation of LPL relative to control incubation (absence of quinacrine, Figure 5 ). This decrease may be due to the inhibition of some basal phospholipase A2 activity by quinacrine. The addition of quinacrine (3 /xM) together with TNF (25 ng) completely abolished the ability of TNF to release LPL bound to the cells ( Figure 5 ). The inhibition of TNF-induced release of LPL by quinacrine and the augmentation of this release by mellitin suggest that phospholipase Aj, activation is an important event in TNF mediated release of LPL.
Since the TNF-stimulated release of arachidonic acid also leads to eicosanoid generation, 17 eicosanoids may mediate TNF-induced release of LPL. To test this hypothesis, we added TNF (100 ng) to the culture medium together with 50 £iM indomethacin, a cyclooxygenase inhibitor, 32 which blocks the synthesis of eicosanoids derived from arachidonic acid. This addition only slightly decreased TNF release of LPL (<20% decrease) suggesting that eicosanoid generation from arachidonic acid is not important in TNF induced release of LPL.
LPL binds to endothelial cells via surface heparan sulfate molecules. 333435 We therefore examined whether the release of LPL in response to TNF was secondary to the release of glycosaminoglycans. Endothelial cell glycosaminoglycans were metabolically labeled with 35 S-sulfate and 3 H-glucosamine. 36 The labeled cells with LPL bound were then incubated with different concentrations of TNF (up to 200 ng/ml) at 37°C for 60 minutes. At each concentration of TNF tested, there was no increased release over a control incubation (no TNF) in the amount of glycosaminoglycan-associated radioactivity in the media ( Figure 6 shows the release at 100 ng/ml TNF). Cellassociated radioactivity also remained unchanged (data not shown). Since insulin and insulin-like growth factors have been shown to stimulate proteoglycan synthesis and secretion in vascular and connective tissues, 3738 insulin treatment was studied as a control. As expected, insulin (100 ng/ml) increased the release of glycosaminoglycans into the media ( Figure 6 ).
Discussion
We demonstrated that TNF treatment caused the release of LPL activity and protein bound to endothelial cells. Such The cells were then incubated in Dulbecco's modified Eagle's medium alone, or of medium containing TNF (100 ng/ml) or insulin (100 /xg/ml) for 1 hour at 37°C. Radiolabeled glycosaminoglycans were precipitated from the media, and the radioactivity was determined. Each bar represents the mean of three experiments±SE.
surfaces, an effect which may regulate lipolysis at the vascular endothelium. Thus, an important new pathogenesis for defective triglyceride hydrolysis and hypertriglyceridemia may be illustrated by our results.
Regulation of the activity of LPL is in many ways more complex than that of most secretory proteins. The steps involved in regulating LPL functions in vivo include not only synthesis and secretion by adipose and muscle cells but also transport to an appropriate binding site on the endothelial cell. In addition, activation by a serum cofactor (apolipoprotein C-ll) 3940 and inactivation and removal of the enzyme from the endothelial cells may modulate LPL activity. Once released from endothelial cells, LPL is thought to be transported to the liver, where it is slowly inactivated and degraded. 12 Our previous studies 20 and those in this report illustrate that the endothelial cell binding of LPL may be an important regulatory site for LPL actions.
Vascular endothelial cells possess cell surface receptors for TNF. 2 Our results demonstrate that TNF causes the release of LPL protein and activity bound to endothelial cells. Colchicine blocks the effect of TNF, suggesting the involvement of a secretory event. Pertussis toxin, which ADP-ribosylates and inactivates certain G proteins, also inhibits TNF-induced release of LPL, suggesting that the release may be coupled through a guanine nucleo-' tide regulatory protein. 41 -44 It is also possible that pertussis toxin may have an unidentified effect on endothelial cells, which blocks the ability of TNF to release LPL. TNF treatment does not alter the amount or secretion of glycosaminoglycans by endothelial cells, suggesting that TNF does not decrease the total number of LPL binding sites.
A reasonable mechanism for TNF-induced release of LPL that is compatible with all of the above observations relates to the release of LPL by arachidonic acid (Fig-ure 4) . LPL molecules have a fatty acid binding site, 12 and our previous studies 20 ' 27 have shown that some types of free fatty acids appear to specifically release this protein from endothelial cells. It is conceivable that arachidonic acid secreted in response to TNF, a step which is pertussis toxin-sensitive 17 and also fulfills the requirement of a colchicine inhibited secretory event, may interact with and release some of the LPL bound to the endothelial cells. Furthermore, a requirement for the activation of phospholipase Aa and subsequent arachidonic acid generation in TNF-induced release of LPL also was demonstrated in the experiments using melitrin and quinacrine. The generation of even small amounts of arachidonic add at or close to the cell membrane site where LPL is bound may be sufficient for the release of endothelial cell-bound LPL.
The in vivo effects of TNF on triglyceride metabolism may be complex. Increases in triglyceride synthesis in humans and diabetic animals have been reported after TNF administration.
1845 TNF also decreases LPL activity in fat tissue. 104847 In addition to effects on adipose tissue, TNF administration rapidly increases plasma and liver LPL activity in several animal species. 10 These results, together with the data presented here, support the hypothesis that TNF releases LPL from endothelium, and the enzyme is then transported via the plasma to the liver. The increased LPL in the liver and decreased LPL activity at its functional location on the endothelial surface may cause a greater flow of free fatty acids (energy) to the liver to meet the acute metabolic demands of inflammatory responses. In this regard, Chajek-Shaul et al. 48 showed that TNF treatment of rats resulted in the uptake of triglyceride-enriched chylomicron remnants by the liver, suggesting a decrease in peripheral triglyceride lipolysis. TNF-mediated rapid release of LPL from the endothelium may be involved in generation of the hypertriglyceridemia, which occurs during infection and in response to administration of endotoxin, both of which trigger the synthesis of TNF (in the host).
Moderate levels of TNF may confer survival advantage with respect to bacterial or viral infection by providing a useful mobilization of energy reserves for the increased metabolic demand. Thus, while one acute effect of TNF is to induce hypertriglyceridemia by loss of endothelial cell-bound LPL, prolonged exposure to TNF may induce cachexia by depleting and depriving peripheral adipose and muscle of free fatty acids.
